why Lyell Immunopharma Inc. [LYEL] is a Good Choice for Investors After New Price Target of $22.00


Lyell Immunopharma Inc. [NASDAQ: LYEL] traded at a high on 03/17/22, posting a 6.02 gain after which it closed the day’ session at $6.34. The company report on March 8, 2022 that Lyell Immunopharma Announces Upcoming Presentation on LYL797 at the American Association for Cancer Research (AACR) 2022 Annual Meeting.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


LYL797 is an investigational ROR1 CAR T-cell therapy incorporating novel reprogramming technologies for solid tumors.

Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, announced today that an abstract has been accepted for poster presentation at the upcoming American Association for Cancer Research (AACR) 2022 Annual Meeting, scheduled for April 8-13 in New Orleans.

The results of the trading session contributed to over 3311711 shares changing hands. Over the past one week, the price volatility of Lyell Immunopharma Inc. stands at 12.72% while the volatility over the past one month is 9.88%.

The market cap for LYEL stock reached $1.52 billion, with 239.38 million shares outstanding and 200.61 million shares in the current float. Compared to the average trading volume of 1.01M shares, LYEL reached a trading volume of 3311711 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Lyell Immunopharma Inc. [LYEL]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LYEL shares is $22.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LYEL stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Morgan Stanley have made an estimate for Lyell Immunopharma Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on July 12, 2021. While these analysts kept the previous recommendation, JP Morgan raised their target price to Overweight. The new note on the price target was released on July 12, 2021, representing the official price target for Lyell Immunopharma Inc. stock. Previously, the target price had yet another raise to $30, while Goldman analysts kept a Buy rating on LYEL stock.

The Average True Range (ATR) for Lyell Immunopharma Inc. is set at 0.63, with the Price to Sales ratio for LYEL stock in the period of the last 12 months amounting to 150.95. The Price to Book ratio for the last quarter was 1.54, with the Price to Cash per share for the same quarter was set at 2.57.

How has LYEL stock performed recently?

Lyell Immunopharma Inc. [LYEL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.31. With this latest performance, LYEL shares dropped by -7.04% in over the last four-week period, additionally sinking by -45.63% over the last 6 months .

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LYEL stock in for the last two-week period is set at 49.24, with the RSI for the last a single of trading hit 49.54, and the three-weeks RSI is set at 48.23 for Lyell Immunopharma Inc. [LYEL]. The present Moving Average for the last 50 days of trading for this stock 6.17, while it was recorded at 6.10 for the last single week of trading.

Lyell Immunopharma Inc. [LYEL]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Lyell Immunopharma Inc. [LYEL] shares currently have an operating margin of -2854.15. Lyell Immunopharma Inc.’s Net Margin is presently recorded at -2682.49.

Return on Total Capital for LYEL is now -36.63, given the latest momentum, and Return on Invested Capital for the company is -34.54. Additionally, LYEL Total Debt to Total Capital is recorded at 137.84, with Total Debt to Total Assets ending up at 117.31.

Lyell Immunopharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 10.60 and a Current Ratio set at 10.60.

Earnings analysis for Lyell Immunopharma Inc. [LYEL]

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LYEL. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Lyell Immunopharma Inc. go to -7.90%.

Insider trade positions for Lyell Immunopharma Inc. [LYEL]

There are presently around $484 million, or 54.90% of LYEL stock, in the hands of institutional investors. The top three institutional holders of LYEL stocks are: MWG MANAGEMENT LTD. with ownership of 20,162,332, which is approximately -0.671% of the company’s market cap and around 1.90% of the total institutional ownership; APOLETTO LTD, holding 15,093,969 shares of the stock with an approximate value of $90.26 million in LYEL stocks shares; and FORESITE CAPITAL MANAGEMENT IV, LLC, currently with $79.43 million in LYEL stock with ownership of nearly 0% of the company’s market capitalization.

Positions in Lyell Immunopharma Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 52 institutional holders increased their position in Lyell Immunopharma Inc. [NASDAQ:LYEL] by around 8,624,070 shares. Additionally, 21 investors decreased positions by around 4,297,879 shares, while 13 investors held positions by with 68,073,603 shares. The mentioned changes placed institutional holdings at 80,995,552 shares, according to the latest SEC report filing. LYEL stock had 25 new institutional investments in for a total of 3,819,747 shares, while 10 institutional investors sold positions of 3,665,522 shares during the same period.